Tobira (TBRA) Large Shareholder Pentwater Buys, Not Sells Following Allergan Deal

September 22, 2016 5:02 PM EDT

News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.

In an interestingly development, large Tobira Therapeutics (NASDAQ: TBRA) shareholder Pentwater Capital did not cash out following the 733% surge in the stock after the acquisition announcement by Allergan (NYSE: AGN). Instead, the firm has added to its position.

The group bought 1,624,200 shares from 09/20-09/22 at prices from $38.87-$39.45, which brings their stake to 3,533,200 shares. Tobira shares closed today at $39.50.

On Tuesday (09/20), Tobira Therapeutics agreed to be acquired for an upfront payment of $28.35 per share, in cash, and up to $49.84 per share in Contingent Value Rights (CVRs) that may be payable based on the successful completion of certain development, regulatory and commercial milestone.

It is clear, Pentwater Capital sees value in the CVR's.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

13Gs, Hedge Funds, Insider Trades, Mergers and Acquisitions, Rumors, Trader Talk

Related Entities

Pentwater Capital, Definitive Agreement

Add Your Comment